OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics, he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight Biologics, a Euronext-listed French biopharma company developing gene therapies for neurodegenerative retinal diseases, where he led the company's financing strategy from the Series B to the IPO on Euronext Paris and a number of follow-on transactions and structured financings.
Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate Finance team and contributed to public offerings and private placements, including the dual listing of the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young in Paris.
He holds master's degrees in international finance from ESGF Paris and in international management from NEOMA Business School.
Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company's financial leadership.
Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented:
'Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and strategic financial planning. He has a clear understanding of what it takes to support innovation through disciplined execution and rigorous cash management. His arrival comes at a time when financial leadership is key to advancing our two late-stage assets and continuing to leverage our research platform. His expertise will further reinforce the management team to prepare the next phase of growth with clarity and focus.'
Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said:
'I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-stage assets in oncology and inflammation, boosted by a highly innovative research platform, the company is well positioned to create meaningful long-term value through clear multiple short-term inflexion points. I look forward to working closely with the leadership team to help unlock the full potential of OSE's innovative pipeline.'
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.
Additional information about OSE Immunotherapeutics assets is available on the Company's website: www.ose-immuno.com. Follow us on LinkedInContacts
Fiona Olivierfiona.olivier@ose-immuno.comSylvie Détrysylvie.detry@ose-immuno.com
Contact Media France: FP2COMFlorence Portejoiefportejoie@fp2com.fr+33 6 07 768 283
Contact Media US:RooneyPartners LLCKate Barrettekbarrette@rooneypartners.com+1 212 223 0561
Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
Attachments
EN_2508_20_CFO_vf
EN_2508_20_CFO_vf
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
SoftBank Sinks 9% as Asia Tech Stocks Follow U.S. Slide
This article first appeared on GuruFocus. SoftBank Group plunged as much as 9.2% Wednesday, leading a regional tech selloff after Wall Street losses tied to a pullback in Nvidia. The Tokyo-listed investment firm has now fallen for a second straight session, days after disclosing a $2 billion investment in Intel (INTC, Financials), whose shares jumped nearly 7% Tuesday in New York. Warning! GuruFocus has detected 10 Warning Signs with INTC. Other Japanese chip stocks dropped, with Advantest down 6.3%, Renesas Electronics off 2.5% and Tokyo Electron slipping 0.8%. The weakness spread across Asia. In Taiwan, TSMC (TSM, Financials) fell 1.7% and Foxconn (HNHPF, Financials) declined 2.2%. In South Korea, SK Hynix dropped 3.3% while Samsung Electronics edged 0.8% higher. The U.S. Commerce Department is weighing taking equity stakes in semiconductor companies that receive funding under the CHIPS and Science Act, according to Reuters. TSMC, Samsung and SK Hynix are among the recipients of U.S. subsidies aimed at boosting domestic chip manufacturing. In Hong Kong, the Hang Seng Tech Index lost 0.9%. Kuaishou Technology slid 4.8%, JD Health International dropped 3.3% and Horizon Robotics declined 2.3%. Heavyweights Alibaba Group and Xiaomi Corp also slipped, down 1.4% and 1.3%, respectively. The broad declines highlight how closely Asia's semiconductor and technology sectors remain tied to U.S. investor sentiment, particularly around Nvidia, whose chips power the latest wave of artificial intelligence applications.
Yahoo
3 hours ago
- Yahoo
Steep Hill Announces Appointment of Director
Toronto, Ontario--(Newsfile Corp. - August 20, 2025) - Steep Hill Inc. (CSE: STPH) ("Steep Hill" or the "Company") is pleased to announce that Ms. Sonia Agustina has been appointed as a Director of the Company, effective August 13, 2025. Ms. Agustina is a Chartered Professional Accountant with over 20 years of financial leadership experience in both public practice and industry, specializing in regulated, high-growth, and publicly listed companies. She currently serves as Chief Financial Officer of Galleon Gold Corp., a TSXV-listed exploration company, where she oversees all aspects of financial strategy, regulatory reporting, and treasury operations. Through her advisory practice, she has supported numerous early-stage and public companies on IPO readiness, M&A, financial compliance, and corporate restructuring. Her industry experience spans mineral resources, cannabis, technology and manufacturing. Sonia is a Chartered Professional Accountant (Ontario) and holds a Bachelor of Administrative Studies (Honours) from York University. In addition, the Company wishes to announce that it has granted an aggregate of 1,300,000 options to purchase common shares of the Company to directors, officers and consultants of the Company, exercisable at a price of $0.065 per common share for a period of five (5) years from the date of grant, in accordance with the terms of the Company's stock option plan. The common shares issuable upon exercise of the options are subject to a statutory hold period of four months and one day from the date of grant. For more information, contact: Sameet Kanade, CEOEmail: 647-876-6525 Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the anticipated completion of the transactions described herein. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company's business. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note. The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 hours ago
- Yahoo
SharpLink Ether Holdings Top $3.1B, Trailing BitMine in Pace of ETH Acquisition
SharpLink Gaming (SBET), the Nasdaq-listed ether (ETH) treasury firm led by Ethereum co-founder Joe Lubin, said it bought 143,593 ETH through last week, bringing total holdings above $3 billion. To finance the purchases, SharpLink raised $537 million in net proceeds during the week ended Aug. 15. The company secured $390 million through a registered direct offering that closed Aug. 11, and an additional $146.5 million via its at-the-market issuance program. The firm reported an average ETH purchase price of $4,648 for last week's acquisitions. That's roughly 8% higher than the asset's current price after the crypto market slid over the past few days, with ETH dropping below $4,300. As of Sunday, SharpLink held 740,760 ETH, worth $3.18 billion at current prices. The Minneapolis-based firm has pursued an aggressive digital asset treasury strategy since its late May pivot, raising funds to accumulate ETH and staking the tokens in exchange for rewards. Even so, its acquisition pace trails competitor BitMine Immersion Technologies (BMNR), which has more than 1.5 million tokens, roughly twice as many as SharpLink. The company said it still had more than $84 million in cash to deploy for future ETH purchases.
